Wild-type p53 gene has properties consistent with it being the product of a tumour suppressor gene. Mutations within highly conserved domains of the p53 gene frequently occur in wide variety of tumour cells including leukaemic cells (Sugimoto et al., 1991; Fenaux et al., 1992; Hu et al., 1992) . The products of mutated p53 gene not only lack normal function but also can convert wild-type p53 to a promoter of cell proliferation and tumour progression (Marshall, 1991) . Recently evidence has accumulated that wild-type p53 can exist in two different conformations; one with a suppressor effect and one with a promoter effect on cell proliferation (reviewed in Milner, 1991; and Ullrich et al., 1992) . These studies have been facilitated by the differential reactivity of the two different conformations with a number of p53 monoclonal antibodies; PAb421, PAbl 801, PAb240 and PAbI620. Thus Milner (1991) has proposed that the suppressor form of p53 is PAb 1620 + /PAb240-and that the promoter form is PAb 1620 -/PAb240 +, the latter is also the immunophenotype of mutant p53.
The blast cells of acute myeloblastic leukaemia (AML) are a convenient model to study the effect of p53 on cell proliferation. Studies of the in vitro growth characteristics of AML blasts have revealed considerable heterogeneity. We have previously classified the growth of AML blasts into four groups depending upon their pattern of growth in a blast cell colony assay. Group 1 cells fail to grow in this system, even when stimulated by exogenous colony-stimulating factors (CSF); group 2 cells form colonies but growth is totally dependent upon exogenous CSFs; group 3 cells exhibit partial autonomous growth which is dependent upon the production of autocrine growth factor but growth can be further stimulated by CSF; finally group 4 cells grow totally autonomously. The autonomous growth of group 3 and group 4 cells was found to be related to the production of autocrine growth factors particularly granulocytemacrophage CSF (GM-CSF) and interleukin-l, (Reilly et al., 1989; Bradbury et al., 1990 ). Here we have studied the expression of p53 in AML blasts with different growth characteristics and the effect of stimulation and inhibition of proliferation on the conformation of p53.
Materials and methods

AML cells
Blood samples were obtained at diagnosis from 34 patients with AML and peripheral blood blast count of >2 x 1091-. The diagnosis of AML was made using FAB criteria following conventional cytochemical stains and surfaces marker analysis. Mononuclear cells were separated by FicollHypaque sedimentation and samples were depleted of T cells by Dynabeads M-450 Pan-T (CD-2) (Dynal, Oslo, Norway). TF-1 which is a human factor-dependent erythroleukaemic cell line (Kitamura et al., 1989) (Reilly et al., 1989) . Cultures were plated in triplicate in the presence or absence of a source of colony-stimulating activity provided by medium conditioned by the 5637-human bladder carcinoma cell line which contains GM-CSF, G-CSF and IL-1. Colonies of >20 cells were counted after 5-7 days in culture. For (Ab-2) recognises an epitope between amino acids 32 and 79 (Banks, 1981) ; PAb240 recognises an epitope between amino acids 156 and 335 (Gannon, 1990) ; PAbl620 was developed by Ball et al. (1984) and has been shown to recognise a conformational epitope specific for wild-type p53 (Ball et al., 1984; Milner & Medcalf, 1991 Group 1 blasts fail to grow in the clonogenic assay used; group 2 blasts are totally dependent upon exogenous growth factors for colony growth; group 3 blasts exhibit partially autonomous growth characteristics; group 4 blasts exhibit totally autonomous growth in vitro. % refers to the frequency of positive cells measured by flow cytometry.
Overall 19 out of 31 (61%) samples were positive with PAbl620. This included 13 out of 14 samples (93%) with characteristics of non-autonomous growth (groups 1 and 2), however, only six out of 17 samples (35%) with characteristics of autonomous growth (groups 3 and 4) were detected by PAbl620. Using PAb421 18 out of 31 samples were positive, again the majority of blasts with non-autonomous growth were positive (12 out of 14 samples) in contrast ony six out of 17 group 3/group 4 blasts were positive (P < 0.01). Thus groups 1 and 2 blasts with non-autonomous growth characteristics co-expressed p53 in both suppressor (PAbl 620 +) and promoter (PAb240 +) conformations whereas blasts with autonomous growth (groups 3 and 4) were more frequently only PAb240 +.
The different patterns of p53 expression between AML blasts with autonomous and non-autonomous growth were further examined by studying one patient (AML-10), at presentation and following relapse. Initially the blasts had group 2 growth characteristics and (Figure 1 ) expressed p53 in both PAb240 (79%) and PAbl620 (46%) conformations. However at relapse the growth characteristics had changed to those of group 3 and the PAbl620 + conformation was no longer detectable. These data suggested that the expression of p53 in AML cells closely related to cell proliferation. To investigate this further we studied the effect of growth stimulation on group 2 blasts.
As shown in Table II , changes in p53 conformation in group 2 blasts induced by growth factors provided by 5637-CM were detected following 48 h of culture. PAbl620 expression was reduced and PAb240 expression increased (Table  II) . Similar results were obtained in the TF-1 factordependent erythroleukaemia cell line. When cell growth was induced by rGM-CSF, PAbl620 expression was present in <5% of cells, however 48 h following withdrawal of GM-CSF, PAb1620 expression was increased to 26%. Conformational change of p53 was also found in groups 3 and 4 blasts treated with an anti-GM-CSF antibody which inhibits proliferation of these cells (Reilly et al., 1989) . In three blasts tested, PAb 1620 expression was increased following incubation with anti-GM-CSF and PAb240 expression was reduced (Table III) .
Discussion
We have investigated the expression and conformation of p53 in blast cells from 34 patients with AML by flow cytometry using four different monoclonal antibodies. In blasts from three patients, p53 was not detectable by any of these antibodies, a finding which had previously been reported by others . Blasts from these three patients all exhibited totally autonomous (group 4) growth in vitro. We have previously shown that the autonomous growth of AML blasts is related to the production of autocrine growth factors including GM-CSF and IL-P (Reilly et al., 1989; Bradbury et al., 1990) . Our data here suggest that the acquisition of autonomous growth characteristics by AML blasts may also involve the inactivation of growth inhibitory proteins such as wild-type p53. We have also recently shown that deletion of retinoblastoma (Rb) protein is common in AML blasts with autonomous growth. It is of interest that blasts from the three patients which were p53 negative were also negative for Rb protein expression (data not shown) a protein which also normally suppresses cell proliferation.
Blast cells from the remaining 31 patients all expressed p53 detected by PAb240. Similar results have recently been reported in chronic myeloid leukaemia cells (Lanza et al., 1991) , also Zhang et al. (1992) detected p53 recognised by PAb240 in 32 out of 37 (86%) of AML samples using immunoprecipitation. However p53 mutations as detected by PCR-SSCP (polymerase chain reaction-single strand conformation polymorphism) and sequence analysis were only detected in three of these samples. Several research groups have already reported that p53 in normal haematopoetic cells is also recognised by PAb240 (Rivas et al., 1992; Lanza et al., 1992; Zhang et al., 1992 ) and indeed we have also detected PAb240 positive normal bone marrow cells (data not shown). Therefore expression of p53 recognised by PAb240 is not evidence for mutant p53 in haematopoietic cells including AML blasts, but rather indicates the presence of wild-type p53 in the promoter conformation.
Unlike other previous reports which have used immunoprecipitation , we detected p53 using the antibody PAbl620 in blasts from 19 out of 31 patients. PAbl620 recognises p53 in the suppressor conformation (Milner & Medcalf, 1991) . Thus our data would suggest that p53 with the suppressor (PAb 1620 + /PAb240 -) and the promoter (PAb 1620 -/PAb240 +) conformation are present within the same cell population. Of interest was the finding that the PAb1620 + conformation was associated with the presence of non-autonomous growth in vitro. However following growth stimulation of group 2 blasts with 5637-CM the expression of PAb1620 fell and that PAb240 increased. We further investigated the effect of growth stimulation on p53 expression in the TF-I erythroleukaemia cell line. TF-1 is a factor-dependent cell line requiring GM-CSF for proliferation (Kitamura et al., 1989) . In active proliferation the cells are PAb240 +.PAbl620 -. However within 48 h of removal of GM-CSF from the cultures, TF-1 cells expressed p53 in the PAbl620 conformation. These data would indicate that the presence of p53 in the PAbl620 + conformation is associated with growth arrest of leukaemic cells even in the presence of p53 in the promoter (PAb240 +) form. Cells which have been stimulated with exogenous growth factors or which produce autocrine growth factors are thus characteristically PAb240 +, PAbl620 -. As a corollary to this treatment of AML blasts with autonomous growth characteristics using anti-GM-CSF which is associated with growth inhibition, was associated with increased PAbl620 expression and reduction in PAb240. In all of these studies expression of PAbl620 was associated with PAb421 expression suggesting that unlike previous studies, PAb421 recognises p53 in the suppressor conformation similar to PAbl620.
The relationship between growth characteristics and p53 expression in AML blasts was further illuminated by studies on one patient's cells at presentation and after relapse. Initially the cells expressed p53 in both promoter and suppressor conformations and exhibited group 2 growth. Analysis at relapse revealed a change in the growth characteristics of the cells with the presence of partially autonomous growth and which were now PAbl620 negative.
It has been suggested that normal function of p53 may be related to cell differentiation and programmed cell death (apoptosis) (Yonish-Rouach et al., 1991) . Thus wild-type p53 induced apoptosis when introduced into murine leukaemic cells which normally lack p53. It is possible that the presence of p53 in the mutant or promoter (PAb240 + /PAbl620-) conformation, or its complete absence in blast cells with autonomous growth may be important in preventing apoptotic cell death in these AML cells.
We have recently shown that patients whose AML cells exhibit autonomous growth characteristics (groups 3 and 4 blasts) have a low remission induction rate and a significantly reduced survival compared to the non-autonomous growth group (Hunter et al., 1993) . The effect of autocrine growth factors in maintaining p53 in the promoter PAb240 + conformation may prevent apoptotic cell death and thus may be one mechanism accounting for the poor survival of this group of patients.
